Form 4: DarioHealth Director Karah Acquires 20,000 Shares

DarioHealth Corp. Director Hila Karah acquired 20,000 shares of common stock as a restricted award, bringing her total beneficial ownership to 30,965 shares, following a recent 20-for-1 reverse stock split.

Summary

• Hila Karah, a Director of DarioHealth Corp. (DRIO), acquired 20,000 shares of common stock on September 11, 2025.
• This acquisition was a restricted share award with a transaction price of $0 per share.
• The restricted share award is scheduled to vest in two equal installments on the last day of each successive annual anniversary after the grant date over a two-year period.
• Following this transaction, Karah beneficially owns a total of 30,965 shares of DarioHealth Corp. common stock.
• The reported number of beneficially owned shares reflects a 20-for-1 reverse stock split that was effected on August 28, 2025.

Sentiment

Score: 7

Explanation: The acquisition of 20,000 restricted shares by a director, while a grant at $0, increases insider ownership and generally signals confidence in the company's future. However, the transaction occurs shortly after a significant 20-for-1 reverse stock split, which can be a concern for investors, tempering the overall positive sentiment.

Positives

• Director Hila Karah received a restricted share award of 20,000 common shares, which increases her equity stake and aligns her interests with those of shareholders.

Negatives

• No direct negatives are reported in this Form 4 filing.

Risks

• No specific risks are detailed in this Form 4 filing.

Future Outlook

The restricted share award of 20,000 shares will vest in two equal installments on the last day of each successive annual anniversary after the grant date (September 11, 2025) over a two-year period.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing.

Industry Context

This Form 4 filing primarily reports an insider transaction and does not contain information related to broader industry trends or competitors.

Comparison to Industry Standards

• Not applicable as this Form 4 reports an insider transaction and does not contain performance metrics for industry comparison.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are reported in this filing.

Related Party Transactions

• Director Hila Karah received a restricted share award of 20,000 common shares from DarioHealth Corp., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The increase in director ownership may be viewed positively as it aligns management interests with shareholder value, though the shares are a grant rather than an open market purchase. The reverse stock split may impact per-share metrics and investor perception.
• Management/Directors: Director Hila Karah's equity stake in the company has increased, further incentivizing her performance and commitment to the company's success.

Next Steps

• First installment of the restricted share award will vest on the last day of the annual anniversary of the grant date (September 11, 2025).
• Second installment of the restricted share award will vest on the last day of the second annual anniversary of the grant date (September 11, 2025).

Key Dates

Recommendation

This Form 4 primarily reports an insider stock grant, which, while increasing director ownership and aligning interests, is compensation rather than an open market purchase. The transaction also follows a 20-for-1 reverse stock split, a corporate action often taken to boost share price or maintain listing requirements, which can be viewed with caution. Without additional financial performance data or strategic updates, a 'hold' recommendation is appropriate as this filing alone does not provide sufficient grounds for a strong buy or sell decision.

Keywords

DarioHealth, DRIO, Hila Karah, Insider Trading, Form 4, Stock Award, Restricted Stock, Director, Reverse Stock Split